Aura Biosciences, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Aura Biosciences, Inc. (AURA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-30
- Aura Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -0.10%.
- Aura Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was -0.30%.
- Aura Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.10%, a 200.00% decline from fiscal 2022.
- Aura Biosciences, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -0.10% 10-K · filed 2026-03-30 | |
| 2024-12-31 | -0.30% 10-K · filed 2026-03-30 | -0.10% 10-K · filed 2025-03-24 |
| 2023-12-31 | -0.10% 10-K · filed 2025-03-24 | |
| 2022-12-31 | 0.10% 10-K · filed 2024-03-27 | |
| 2021-12-31 | -0.30% 10-K · filed 2023-03-15 | |
| 2020-12-31 | -0.40% 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |